缉毒局可以加快大麻医学研究;专家们敦促更快的批准和明确的准则,以便能够在年底进行试验。 DEA can speed medical cannabis research; experts urge faster approvals and clear guidelines to enable trials by year’s end.

尽管国会努力限制大麻改期,但禁毒局仍然有权加快大麻医学研究。 Despite congressional efforts to restrict marijuana rescheduling, the DEA still has the authority to accelerate medical cannabis research. 研究和制造登记方面的持续拖延,加上过程缓慢和不明确,阻碍了慢性疼痛和创伤后应激障碍等疾病的临床试验。 Ongoing delays in research and manufacturing registrations, along with a slow and unclear process, are hindering clinical trials for conditions like chronic pain and PTSD. 虽然林业发展局已经批准了大麻衍生的治疗方法,如甲状腺炎,但药品管理局及时采取行动对于推进循证药物至关重要。 While the FDA has approved cannabis-derived treatments like Epidiolex, timely DEA action is essential to advance evidence-based medicine. 专家敦促DEA加快申请,制定明确的时间表,为FDA调整的研究创建"临床快速通道",发布GMP指导,调整配额以满足试验需求,并组建公私工作组,在没有新法律的情况下,可以在年底前进行新的试验和制造. Experts urge the DEA to fast-track applications, establish clear timelines, create a “Clinical Fast Lane” for FDA-aligned studies, issue GMP guidance, adjust quotas to match trial demand, and form a public-private working group—steps that could enable new trials and manufacturing by year’s end without new laws.